Öz
Kaynakça
- Referans1) Heo J, Cho M, Kim HH, Shin YM, Jang HJ, Park HK, Kim CM, Kim GH, Kang DH, Song GA, Yang US. Detection of YMDD motif mutants by oligonucleotide chips in lamivudine-untreated patients with chronic hepatitis B virus infection. J Korean Med Sci. 2004 ;19:541–5.
- Referans2). Lok ASF, McMahon BJ. Chronic hepatitis B. Hepatology 2007 feb;45; 507-539. Referans3) Tacke F, Gehrke C, Luedde T, Heim A, Manns MP, Trautwein C. Basal core promoter and precore mutations in the hepatitis B virus genome enhance replication efficacy of Lamivu-dine-resistant mutants. J Virol. 2004 Aug;78(16):8524-35.
- Referans4) Tassopoulos NC, Volpes R, Pastore G, Heathcote J, Buti M, Goldin RD, Hawley S, Barber J, Condreay L, Gray DF. Efficacy of lamivudine in patients with hepatitis B e antigen-negative/hepatitis B virus DNA-positive (precore mutant) chronic hepatitis B. Lamivudine Precore Mutant Study Group. Hepatology. 1999 Mar;29(3):889-96.
- Referans5) Chayama K, Suzuki Y, Kobayashi M, Tsubota A, Hashimoto M, Miyano Y, et al. Emergence and takeover of YMDD motif mutant hepatitis B virus during long-term lamivudine therapy and retakeover by wild type after cessation o f therapy. Hepatology 1998: 1711-27.
- Referans6) Allen MI, Gauthier J, DesLauriers M, Bourne EJ, Carrick KM, Baldanti F, et al. Tw o sensitive PCR-based methods for detection of hepatitis B virus variants associated with reduced susceptibility to lamivudine. J Clin Microbiol 1999 oct: 3338—47., 37.
- Referans7) Kirishima T, Okanoue T, Daimon Y, Itoh Y, Nakamura H, Morita A, et al. Detection of YMDD mutant using a novel sensitive method in chronic liver disease type B patients before and during lamivudine treatment. J Hepatol 2002; 37 :259—65.
- Referans8) Kobayashi S, Ide T, Sata M. Detection of YMDD motif mutations in some lamivudine-untreated asymptomatic hepatitis B virus carriers. J Hepatol 2001; 34: 584—6.
- Referans9) Kirishima T, Okanoue T, Daimon Y, Itoh Y, Nakamura H, Morita A, Toyama T, Minami M. Detection of YMDD mutant using a novel sensitive method in chronic liver disease type B patients before and during lamivudine treatment. J Hepatol. 2002; 37: 259–265.
- Referans10) Matsuda M, Suzuki F, Suzuki Y, Tsubota A, Akuta N, Hosaka T, Someya T, Kobayashi M, Saitoh S, Arase Y, et al. YMDD mutants in patients with chronic hepatitis B before treatment are not selected by lamivudine. J Med Virol. 2004; 74: 361–366.
- Referans11) Huang ZM, Huang QW, Qin YQ, et al. Clinical characteristics and distribution of hepatitis B virus genotypes in Guangxi Zhuang population. World J Gastroenterol 2005; 11; 6525-9.
- Referans12) Heo J, Cho M, Kim HH, Shin YM, Jang HJ, Park HK, Kim CM, Kim GH, Kang DH, Song GA, Yang US. Detection of YMDD motif mutants by oligonucleotide chips in lamivudine-untreated patients with chronic hepatitis B virus infection. J Korean Med Sci. 2004; 19: 541–45.
- Referans13) Tunçbilek S, Köse S, Elaldi A, Akman S. Lamivudine resistance in untreated chronic hepatitis B patients in Turkey. Turk J Gastroenterol. 2008; 19; 99–103.
- Referans14) Ye XG, Wang RL, Guo HB. Detection and analysis of YMDD mutate genes in patients of chronic hepatitis B before being treated. Zhonghua Jianyan Yixue Zazhi 2002; 25; 248-51.
Öz
Objective:
Prevalence of lamivudine resistance in treatment-naïve hepatitis B patients shows variation among populations. The present study aimed to determine the prevalence of lamivudine
resistance in treatment-naïve chronic hepatitis B (CHB) patients followed in
Turkish population.
Method:
The study comprised 71
chronic hepatitis B patients that have never received treatment for chronic
hepatitis B infection before (treatment-naïve). HBV DNA was detected
quantitatively by real-time polymerase chain reaction (RT-PCR) method in serum
samples collected from the patients. Sequence analysis and reverse
hybridization by string method were used to determine Lamivudine motif mutants.
Liver biopsy was performed in all patients. Serum samples collected were used
to determine HBeAg and anti-HBeAb levels.
Results:
Of the 71 patients
participated in the study. Mutation was detected in a total of 8 patients and
the prevalence was 11.3% (8/71). The prevalence of mutation was 8.3% (4/48) in
HBeAg-negative patients and it was lower than HBeAg-positive patients, in whom
the prevalence was 17% (4/23) (p=0.01). Comparing the patients with and without
mutation in terms of demographic characteristics, ALT levels, HAI and fibrosis
scores, no statistically significant difference was determined (p=0.29).
Conclusions:
In the present study, the
prevalence of mutation was 11.3% in treatment-naïve chronic hepatitis B
patients. Therefore, determining local
prevalence for all populations and planning the treatment accordingly may
prevent future complications and thereby enhance efficacy of treatment. Choosing drugs with low resistance
profile and starting treatment considering this resistance.
Anahtar Kelimeler
Kaynakça
- Referans1) Heo J, Cho M, Kim HH, Shin YM, Jang HJ, Park HK, Kim CM, Kim GH, Kang DH, Song GA, Yang US. Detection of YMDD motif mutants by oligonucleotide chips in lamivudine-untreated patients with chronic hepatitis B virus infection. J Korean Med Sci. 2004 ;19:541–5.
- Referans2). Lok ASF, McMahon BJ. Chronic hepatitis B. Hepatology 2007 feb;45; 507-539. Referans3) Tacke F, Gehrke C, Luedde T, Heim A, Manns MP, Trautwein C. Basal core promoter and precore mutations in the hepatitis B virus genome enhance replication efficacy of Lamivu-dine-resistant mutants. J Virol. 2004 Aug;78(16):8524-35.
- Referans4) Tassopoulos NC, Volpes R, Pastore G, Heathcote J, Buti M, Goldin RD, Hawley S, Barber J, Condreay L, Gray DF. Efficacy of lamivudine in patients with hepatitis B e antigen-negative/hepatitis B virus DNA-positive (precore mutant) chronic hepatitis B. Lamivudine Precore Mutant Study Group. Hepatology. 1999 Mar;29(3):889-96.
- Referans5) Chayama K, Suzuki Y, Kobayashi M, Tsubota A, Hashimoto M, Miyano Y, et al. Emergence and takeover of YMDD motif mutant hepatitis B virus during long-term lamivudine therapy and retakeover by wild type after cessation o f therapy. Hepatology 1998: 1711-27.
- Referans6) Allen MI, Gauthier J, DesLauriers M, Bourne EJ, Carrick KM, Baldanti F, et al. Tw o sensitive PCR-based methods for detection of hepatitis B virus variants associated with reduced susceptibility to lamivudine. J Clin Microbiol 1999 oct: 3338—47., 37.
- Referans7) Kirishima T, Okanoue T, Daimon Y, Itoh Y, Nakamura H, Morita A, et al. Detection of YMDD mutant using a novel sensitive method in chronic liver disease type B patients before and during lamivudine treatment. J Hepatol 2002; 37 :259—65.
- Referans8) Kobayashi S, Ide T, Sata M. Detection of YMDD motif mutations in some lamivudine-untreated asymptomatic hepatitis B virus carriers. J Hepatol 2001; 34: 584—6.
- Referans9) Kirishima T, Okanoue T, Daimon Y, Itoh Y, Nakamura H, Morita A, Toyama T, Minami M. Detection of YMDD mutant using a novel sensitive method in chronic liver disease type B patients before and during lamivudine treatment. J Hepatol. 2002; 37: 259–265.
- Referans10) Matsuda M, Suzuki F, Suzuki Y, Tsubota A, Akuta N, Hosaka T, Someya T, Kobayashi M, Saitoh S, Arase Y, et al. YMDD mutants in patients with chronic hepatitis B before treatment are not selected by lamivudine. J Med Virol. 2004; 74: 361–366.
- Referans11) Huang ZM, Huang QW, Qin YQ, et al. Clinical characteristics and distribution of hepatitis B virus genotypes in Guangxi Zhuang population. World J Gastroenterol 2005; 11; 6525-9.
- Referans12) Heo J, Cho M, Kim HH, Shin YM, Jang HJ, Park HK, Kim CM, Kim GH, Kang DH, Song GA, Yang US. Detection of YMDD motif mutants by oligonucleotide chips in lamivudine-untreated patients with chronic hepatitis B virus infection. J Korean Med Sci. 2004; 19: 541–45.
- Referans13) Tunçbilek S, Köse S, Elaldi A, Akman S. Lamivudine resistance in untreated chronic hepatitis B patients in Turkey. Turk J Gastroenterol. 2008; 19; 99–103.
- Referans14) Ye XG, Wang RL, Guo HB. Detection and analysis of YMDD mutate genes in patients of chronic hepatitis B before being treated. Zhonghua Jianyan Yixue Zazhi 2002; 25; 248-51.
Ayrıntılar
| Birincil Dil | İngilizce |
|---|---|
| Konular | Sağlık Kurumları Yönetimi |
| Bölüm | Medical Science Research Makaleler |
| Yazarlar | |
| Yayımlanma Tarihi | 30 Eylül 2019 |
| Kabul Tarihi | 25 Eylül 2019 |
| Yayımlandığı Sayı | Yıl 2019 |